Integrating Shared Decision-Making into Management Plans for Patients with Schizophrenia
Time: 7:00 PM - 8:00 PM ET
Schizophrenia, marked by psychosis, apathy, social withdrawal, and cognitive impairment, has three symptom groups: positive, negative, and cognitive deficits. It leads to high mortality rates, functional impairment, and poor HRQoL. Treatment guidelines recommend combined pharmacologic and psychological approaches, but many current agents fail to address negative symptoms or cognitive dysfunction, necessitating new treatments.
This program is designed to inform clinicians about new and experimental treatments for schizophrenia, focusing on those targeting negative symptoms and cognitive deficits. It will help clinicians understand the impact of schizophrenia, current treatments, and shared decision-making to enhance patient outcomes. In addition, it will educate and empower clinicians treating adult schizophrenia patients, offering opportunities to learn from experts, apply new data, and improve patient care.
Sanjai Rao, MD, DFAPA
Associate Residency Training Director
University of California, San Diego
Site Director, Residency Training
VA Medical Center, San Diego, CA
San Diego, CA
Dawn Velligan, PhD
Director, Division of Community Recovery, Research and Training
Henry B. Dielmann Chair, Department of Psychiatry
University of Texas Health Science Center in San Antonio
San Antonio, TX
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this live activity for 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.